Cell

Vyriad Announces Oral Presentation at the 27th American Society of Gene & Cell Therapy Annual Meeting

Retrieved on: 
Monday, May 6, 2024
Toxicity, Society, Gene, Cell

ROCHESTER, Minn., May 6, 2024 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced that its abstract, In Vivo Generation of αCD19-CAR T Cells Using a Novel LV-based Platform Successfully Clears Advanced NALM-6 Tumor without Noticeable Toxicity, has been selected for an oral presentation at the 27th American Society of Gene & Cell Therapy Annual Meeting to be held May 7-11, 2024, in Baltimore, Maryland.

Key Points: 
  • ROCHESTER, Minn., May 6, 2024 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced that its abstract, In Vivo Generation of αCD19-CAR T Cells Using a Novel LV-based Platform Successfully Clears Advanced NALM-6 Tumor without Noticeable Toxicity, has been selected for an oral presentation at the 27th American Society of Gene & Cell Therapy Annual Meeting to be held May 7-11, 2024, in Baltimore, Maryland.
  • Vyriad's presentation will discuss progress in developing its highly targeted, efficient, serum-stable and durable lentiviral vector technology to deliver genetic payloads directly and specifically to CD3+ T cells in vivo.

ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events

Retrieved on: 
Monday, May 6, 2024
International Society, ISAC, Research, Cell, Drug discovery, Therapy, AAI, Society, Datasheet, ARVO, Growth, Video game

TOKYO, May 6, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of its updated website .

Key Points: 
  • TOKYO, May 6, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of its updated website .
  • The events will showcase both internal research and development achievements as well as presentations from VisionSort customers on the application of the platform to advance research and therapeutic development efforts.
  • "A year ago we launched VisionSort and had just been recognized for technology innovation at CYTO, the premiere international cytometry meeting," said Janette Phi, Chief Business Officer at ThinkCyte.
  • For more information about ThinkCyte's upcoming events, visit: https://thinkcyte.com/conferences/ https://doi.org/10.1016/j.stemcr.2023.12.001

ION Storage Systems Commissions One of the Country's Largest Solid-State Battery Manufacturing Facilities

Retrieved on: 
Monday, May 6, 2024
SSB, University, DOE, Cell, ION, Safety, Research, Heart, MD, Primary energy, Growth, Cobalt, Money, Saint-Gobain, Inflation, Child, CREB, Temperature, Mining, Architecture, Defense, Nickel, Electric battery

Senator Chris Van Hollen, Congressman Glenn Ivey and others, ION Storage Systems (ION), a Maryland-based manufacturer of safe, high energy density, fast-charging solid-state batteries (SSBs) commissioned one of the largest SSB manufacturing facilities in the United States.

Key Points: 
  • Senator Chris Van Hollen, Congressman Glenn Ivey and others, ION Storage Systems (ION), a Maryland-based manufacturer of safe, high energy density, fast-charging solid-state batteries (SSBs) commissioned one of the largest SSB manufacturing facilities in the United States.
  • Traditional Li-ION batteries simply haven't been up to the task," said Ricky Hanna, CEO of ION Storage Systems.
  • "As we transition to cleaner energy sources and reduce pollution, we need improved battery and energy storage technology.
  • "The commissioning of the state-of-the-art production facility in Beltsville is a great leap forward for ION Storage Systems in safe green battery technology.

BioIVT Highlights its Focus on Cell and Gene Therapy in Spring Industry Events

Retrieved on: 
Monday, May 6, 2024
International Society, QA/QC, Cell, CGT, Different, Gene, Society, ISCT, Supply chain, Medical device

"At BioIVT, we view cell and gene therapy as a masterpiece in the making with dedicated researchers serving as the artists behind the canvas, and we are proud to provide the essential materials and the spark of inspiration for the next research breakthroughs," said Jain. "Our fit-for-purpose solutions provide flexibility in the supply chain to mitigate risks to our customers' CGT pipeline--from R&D through clinical phases of development. We look forward to networking with the top minds in cell and gene therapy research at ASGCT and ISCT and sharing how BioIVT's team can support their developments."

Key Points: 
  • WESTBURY, N.Y., May 6, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will be attending two leading industry events focused on cell and gene therapy research, developments and breakthroughs.
  • From May 7 – 11, a team from BioIVT will attend the American Society of Gene and Cell Therapy Annual Meeting (ASGCT) in Baltimore and from May 29 – June 1, a team will attend the International Society of Cell and Gene Therapy Annual Meeting (ISCT) in Vancouver, Canada.
  • BioIVT will have a booth at each event detailing the art of cell and gene therapy, which highlights how BioIVT provides researchers with the resources necessary to develop and fuel their next breakthroughs.
  • We look forward to networking with the top minds in cell and gene therapy research at ASGCT and ISCT and sharing how BioIVT's team can support their developments."

Red light therapy for repairing spinal cord injury passes milestone

Retrieved on: 
Monday, May 6, 2024
SCI, University, Patient, Protein, Cell, Skin, Tissue, Survival, Research, Human, Light, Sensation, Translational medicine, Spinal cord, Movement, Biological engineering, University of Birmingham, Regeneration, Microscope

BIRMINGHAM, England, May 6, 2024 /PRNewswire/ -- Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light.

Key Points: 
  • BIRMINGHAM, England, May 6, 2024 /PRNewswire/ -- Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light.
  • The method, invented by University of Birmingham scientists and patented by University of Birmingham Enterprise , delivers light directly to the site of the injury.
  • Professor Ahmed said: "The effect of 660nm light was both neuroprotective, meaning it improved survival of nerve cells, and neuroregenerative, meaning it stimulated nerve cell growth."
  • The researchers also investigated the effect of light therapy in preclinical models of SCI, using an implantable device and transcutaneous delivery with the light source placed against the skin.

Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Monday, May 6, 2024
Gene therapy, Abstract, UTR, Machine learning, RNA therapeutics, RNA, Cell, Ginkgo, B cell, Automation, DNA, Therapy, Gene, Society, Acquisition, Messenger, Annual general meeting, NK, Vaccine

Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.

Key Points: 
  • Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.
  • These presentations demonstrate the power of Ginkgo's platform to drive innovation in the discovery and development of genetic medicines.
  • The addition of Patch Bio's assets opens up additional commercial opportunities in gene therapy, cell therapy, and RNA therapeutics and has the potential to accelerate progress on current programs.
  • Information on the poster presentations and oral presentation are listed below, and the full abstracts are available on the ASGCT meeting website .

Red light therapy for repairing spinal cord injury passes milestone

Retrieved on: 
Monday, May 6, 2024
SCI, University, Patient, Protein, Cell, Skin, Tissue, Survival, Research, Human, Light, Sensation, Translational medicine, Spinal cord, Movement, Biological engineering, University of Birmingham, Regeneration, Microscope

BIRMINGHAM, England, May 6, 2024 /PRNewswire/ -- Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light.

Key Points: 
  • BIRMINGHAM, England, May 6, 2024 /PRNewswire/ -- Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light.
  • The method, invented by University of Birmingham scientists and patented by University of Birmingham Enterprise , delivers light directly to the site of the injury.
  • Professor Ahmed said: "The effect of 660nm light was both neuroprotective, meaning it improved survival of nerve cells, and neuroregenerative, meaning it stimulated nerve cell growth."
  • The researchers also investigated the effect of light therapy in preclinical models of SCI, using an implantable device and transcutaneous delivery with the light source placed against the skin.

Quick understanding of JA Solar's 2023 annual report

Retrieved on: 
Saturday, May 4, 2024
JA Solar Holdings, ROA, Silicon, Annual report, Cell, JA, EPS, Renewable energy

Its financial prowess shines through with impressive indicators: EPS at 2.14 yuan per share, up by 25.15%, net profit margin at 8.82% (up by 1.23 percentage points), and gross margin at18.13% (up by 3.35 percentage points).

Key Points: 
  • Its financial prowess shines through with impressive indicators: EPS at 2.14 yuan per share, up by 25.15%, net profit margin at 8.82% (up by 1.23 percentage points), and gross margin at18.13% (up by 3.35 percentage points).
  • As of Q1 2024, JA Solar has achieved a cumulative shipment of 201GW, and its production capacities across silicon wafers, cells, and modules are set to surpass 100GW each in 2024.
  • With a projected shipment target of 85-95GW, its scale manufacturing advantage will further solidify.
  • Click to get more infomation about JA Solar 2023 Annual Report.

Quick understanding of JA Solar's 2023 annual report

Retrieved on: 
Saturday, May 4, 2024
JA Solar Holdings, Multimedia, ROA, Silicon, Annual report, Cell, JA, EPS, Renewable energy

With a weighted average ROA of 22.52%, its profitability remains industry-leading.

Key Points: 
  • With a weighted average ROA of 22.52%, its profitability remains industry-leading.
  • As of Q1 2024, JA Solar has achieved a cumulative shipment of 201GW, and its production capacities across silicon wafers, cells, and modules are set to surpass 100GW each in 2024.
  • Click to get more infomation about JA Solar 2023 Annual Report.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/quick-understanding-of-ja-solar...
    SOURCE JA Solar Technology Co., Ltd.

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Retrieved on: 
Friday, May 3, 2024
Cancer, Abstract, Cell, ADR, Patient, Gene, Society, IPSC, SLE, Therapy, SAN

SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.

Key Points: 
  • SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.
  • At the ASGCT conference, the Company will present multiple preclinical studies displaying the function of FT522 using peripheral blood mononuclear cells (PBMCs) sourced from unmatched donors with systemic lupus erythematosus (SLE).
  • These preclinical data demonstrate rapid and deep B-cell depletion, enhanced functional persistence, and elimination of alloreactive host immune cells, indicating that FT522 may deliver therapeutic benefit to patients with autoimmune diseases without requiring administration of conditioning chemotherapy.
  • Late-breaking abstracts are available on the ASGCT Annual Meeting website .